NCT07631013
Phase 1 Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cell In Patients With Oral Premalignant Lesions
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 3 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Recruitment opened
- Start date changed from estimate of Dec 31, 2026 to Oct 30, 2026
- Site details revised
- Notable Eligibility criteria expanded, about 39 words
- Interventions: TROP2 CAR/IL-15 TGFBR2 KO NK cells (Drug) to TROP2 CAR/IL-15 TGFBR2 KO NK cells (Drug)
- Study description expanded, about 4 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Safety and Adverse Events (AEs)
Timeframe: Through study completion; an average of 1 year
Arms and interventions
ESC/EXP: Phase 1 Part 1-ESC and Part 2-EXP Treatment with TROP2 CAR/IL-15 TGFBR2 KO NK CellsExperimental
Participants will receive 2 TGFBR2 TROP2 CAR/IL15 CAR injections on Day 0 and Day 21 at the assigned dose level
Drugs: TROP2 CAR/IL-15 TGFBR2 KO NK cells
Sites
1 site in 1 country
- MD Anderson Cancer CenterHouston, Texas, United States